proportion of TST conversion during immunotherapy was found. According to the immunomodulatory therapy, no differences were found among latent TB patients, active TB disease and no infection with the use of conventional DMARD therapy, but a positive association between latent TB and the use of biologic therapy was recognized. Low prevalences of opportunistic infections (i.e., Hepatitis B and C, syphilis and HIV) were found in this cohort, dispite the frequent use of biologic therapy. Conclusions: In a TB-endemic population, higher prevalences of latent and active TB were found in patients with SpAs, when compared to the general population. Complete infectious screening is mandatory in patients under consideration of biologic agents, and close follow-up must be done to recognize TST conversion. (2). Objectives: To analyze the influence of gender on disease patterns and therapeutic approach in a large cohort of Colombian patients with SpAs. Methods: A cross-sectional study was conducted in 621 patients with SpAs, in whom clinical and therapeutic characteristics were analyzed based on gender. Statistical association was examined by means of Chi-square tests, Mann-Whitney test, and logistic regression analyses.
Background: Hip involvement is the most frequent extraspinal arthritic manifestation of Ankylosing Spondylitis (AS) and a common cause of disability. It is present in 24% to 36% of AS patients, leading to total hip replacement (THR) in 5%. Objectives: To examine the prevalence of hip arthritis in patients with AS under TNF-inhibitor (TNFi) treatment, to identify predictors of its development and possible gender differences. Methods: Consecutive TNFi-naïve AS patients (fulfilling the modified New York criteria) who were eligible for TNFi treatment were included. At baseline (before the start of TNFi), disease activity and function were recorded by BASDAI, ASDAS-CRP/ESR, BASFI and BASMI. Anteroposterior x-rays of the pelvis and lateral x-rays of cervical and lumbar spine were obtained at baseline and scored according to the BASRI-hip scoring system and mSASSS. Hip involvement was assessed both clinically (as pain, reduced range of motion and intermalleolar distance) and radiographically (BASRI-h score ≥2 was defined as definitive hip involvement). Mann-Whitney, two-sample t-test and logistic regression analysis were applied. The groups' averages were expressed as mean±SD, or median (IQR) according to the normality of data. Results: 298 consecutive AS patients (214 men, age: 49±12years (mean±SD), disease duration: 23.8±11.8 years) were included. Definite hip involvement was detected in 113/298 (38%) patients. Bilateral THR and unilateral THR underwent 10/298 (3.4%) and 9/298 (3%) patients respectively. No gender difference in the prevalence of hip arthritis was observed (females: 26/84 (31%) vs. males 87/214 (40.8%). The patients with hip arthritis compared to those without had significantly higher disease activity scores (BASDAI (6.1±1.7 vs. 5.5±1.9, p=0.008), ASDAS-CRP (3.9±0.8 vs. 3.4±0.9, p=0.0001), Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of conventional treatment in ankylosing spondylitis (AS). In case of insufficient response, tumor necrosis factor-alpha (TNF-α) inhibitors are available. Still little is known about concomitant NSAID use. Objectives: To investigate the longitudinal association between disease activity and NSAID use in established AS patients. Methods: The present analysis is part of the GLAS cohort, an ongoing longitudinal observational axial spondyloarthritis (SpA) cohort study in daily clinical practice. During 52 weeks of follow-up, NSAID use was recorded prospectively. The ASAS-NSAID index was calculated using the dosage and frequency assessed retrospectively from clinical records. Disease activity was assessed using ASDAS, BASDAI, and serum CRP levels. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. NSAID use was analyzed using 4 parameters: NSAID use (yes/no), ASAS-NSAID index, low on demand use (index ≥10 versus <10), and high use (index ≥90 versus <90). Analyses were stratified for treatment regimen: patients starting TNF-α inhibitors and patients on conventional treatment. Results: Of the 393 included AS patients, 67% were male, mean age was 44±13 years, median symptom duration 15 years (IQR 8-24), and 79% were
